251 525

Cited 5 times in

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

DC Field Value Language
dc.contributor.author김법우-
dc.contributor.author김석모-
dc.contributor.author김수영-
dc.contributor.author김준원-
dc.contributor.author박정수-
dc.contributor.author이용상-
dc.contributor.author이익재-
dc.contributor.author장항석-
dc.contributor.author장호진-
dc.contributor.author전태주-
dc.date.accessioned2020-12-01T17:20:46Z-
dc.date.available2020-12-01T17:20:46Z-
dc.date.issued2020-09-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180226-
dc.description.abstractBackground: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies. Methods: This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received lenvatinib between October 2015 and February 2018. Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years; 61.1% female). Six [33.3%] had resectable disease that progressed after a combination of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease that progressed after radiation treatment and chemotherapy. Study endpoints were overall survival (OS) and change in volume of the largest tumor assessed via imaging. Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64-839 days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor volume increases of 9-10%. The other 16 patients (88.9%) had tumor volume reductions of 2-69%. Six patients (33.3%) had tumor volume reductions ≥50%. Conclusions: In patients with ATC who had progressed on prior therapy, addition of lenvatinib could improve survival duration and reduce tumor volume. Further studies of lenvatinib in ATC are warranted.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherFrontiers Research-
dc.relation.isPartOfFRONTIERS IN ENDOCRINOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleSurvival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorSoo Young Kim-
dc.contributor.googleauthorSeok-Mo Kim-
dc.contributor.googleauthorJun Won Kim-
dc.contributor.googleauthorIk Jae Lee-
dc.contributor.googleauthorTae Joo Jeon-
dc.contributor.googleauthorHojin Chang-
dc.contributor.googleauthorBup-Woo Kim-
dc.contributor.googleauthorYong Sang Lee-
dc.contributor.googleauthorHang-Seok Chang-
dc.contributor.googleauthorCheong Soo Park-
dc.identifier.doi10.3389/fendo.2020.00599-
dc.contributor.localIdA00491-
dc.contributor.localIdA00542-
dc.contributor.localIdA04725-
dc.contributor.localIdA00958-
dc.contributor.localIdA01646-
dc.contributor.localIdA02978-
dc.contributor.localIdA03055-
dc.contributor.localIdA03488-
dc.contributor.localIdA03496-
dc.contributor.localIdA03557-
dc.relation.journalcodeJ03412-
dc.identifier.eissn1664-2392-
dc.identifier.pmid32982983-
dc.subject.keywordanaplastic thyroid cancer-
dc.subject.keywordlenvatinib-
dc.subject.keywordretrospective study-
dc.subject.keywordthyroid carcinoma-
dc.subject.keywordtyrosine kinase inhibitor-
dc.contributor.alternativeNameKim, Bup Woo-
dc.contributor.affiliatedAuthor김법우-
dc.contributor.affiliatedAuthor김석모-
dc.contributor.affiliatedAuthor김수영-
dc.contributor.affiliatedAuthor김준원-
dc.contributor.affiliatedAuthor박정수-
dc.contributor.affiliatedAuthor이용상-
dc.contributor.affiliatedAuthor이익재-
dc.contributor.affiliatedAuthor장항석-
dc.contributor.affiliatedAuthor장호진-
dc.contributor.affiliatedAuthor전태주-
dc.citation.volume11-
dc.citation.startPage599-
dc.identifier.bibliographicCitationFRONTIERS IN ENDOCRINOLOGY, Vol.11 : 599, 2020-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.